Skip to main content
Livermore
Livermore
ZHEN

Puma Biotechnology, Inc.

PBYI
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001401667

In the last 90 days, Puma Biotechnology, Inc. insiders filed 0 open-market purchases and 5 sales; 160 institutions reported holding it in 13F filings for Q2 2026, worth $313.6M in total; no superinvestor holds it.

Holders of 5% or more of PBYI

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Puma Biotechnology, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of PBYI
HolderLatest formStakeChangeFirst filedLatest filingFiling
Acorn Bioventures, L.P.13G/A8.00%3.94M shares+1.30 ppfrom 6.70%Nov 14, 20242 filingsFeb 14, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on Puma Biotechnology, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on PBYI
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 14, 202512:14 PM ETAcorn Bioventures, L.P.and 4 others13G/A8.00%3.94M shares+1.30 ppfrom 6.70%Dec 31, 2024SEC
Feb 14, 202511:11 AM ETFrazier Life Sciences Public Fund, L.P.and 13 others13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
Feb 14, 20258:34 AM ETCamber Capital Management LPand 1 other13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
Feb 3, 20254:00 PM ETMillennium Management LLCand 3 others13G/A3.90%1.89M shares–Below 5%Dec 31, 2024SEC
Nov 14, 202412:12 PM ETAcorn Bioventures, L.P.and 4 others13G/A6.70%3.28M shares–Sep 30, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Puma Biotechnology, Inc. shares.

No Form 144 notices for Puma Biotechnology, Inc. are on file.